Blog
About

2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.

      The Journal of clinical investigation

      immunology, Animals, Antibodies, Monoclonal, therapeutic use, Antibodies, Monoclonal, Humanized, Autoimmune Diseases, drug therapy, Cytokine Receptor gp130, Humans, Inflammation, Interleukin-6, Neoplasms, Receptors, Interleukin-6, genetics, Signal Transduction

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The successful treatment of certain autoimmune conditions with the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the β-receptor subunit glycoprotein 130 (gp130). In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator. Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.

          Related collections

          Author and article information

          Journal
          21881215
          3163962
          10.1172/JCI57158

          Comments

          Comment on this article